secwatch.observer — SEC 8-K summary
======================================

Issuer:     Tvardi Therapeutics, Inc. (TVRD)
CIK:        0001346830
Form:       8-K
Filed at:   2024-03-04T23:59:59+00:00
Accession:  0001104659-24-030494
Event type: earnings
Sentiment:  negative
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cara Therapeutics reports Q4 net loss $0.59/share; prioritizes NP program, cash runway extended to 2026
--------------------------------------------------------------------------------

- Net loss Q4 $32.3M ($0.59 per share) vs $30.3M ($0.56) prior year; full year loss $118.5M ($2.19) vs $85.5M ($1.59).
- Total revenue Q4 $3.0M (down from $3.3M); FY 2023 $21.0M (down from $41.9M) on lower KORSUVA injection sales.
- Completed enrollment of KOURAGE 1 Part A (214 patients); topline efficacy/safety data expected Q3 2024.
- KORSUVA injection Q4 net sales $5.0M; TDAPA expires March 31, 2024; future reimbursement under ESRD PPS bundle.
- Cash $100.8M at Dec 31, 2023; cash runway extended to 2026 via clinical prioritization, RIF, and HCR royalty deal ($36.5M net).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1346830/000110465924030494/0001104659-24-030494-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1346830/000110465924030494/tm247839d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-030494

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer